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Abstract
The microbiota of the human metaorganism is not a mere bystander. These microbes have 
coevolved with us and are pivotal to normal development and homoeostasis. Dysbiosis of the GI 
microbiota is associated with many disease susceptibilities, including obesity, malignancy, liver 
disease and GI pathology such as IBD. It is clear that there is direct and indirect crosstalk between 
this microbial community and host immune response. However, the precise mechanism of this 
microbial influence in disease pathogenesis remains elusive and is now a major research focus. 
There is emerging literature on the role of the microbiota in the pathogenesis of autoimmune 
disease, with clear and increasing evidence that changes in the microbiota are associated with 
some of these diseases. Examples include type 1 diabetes, coeliac disease and rheumatoid arthritis, 
and these contribute significantly to global morbidity and mortality. Understanding the role of the 
microbiota in autoimmune diseases may offer novel insight into factors that initiate and drive 
disease progression, stratify patient risk for complications and ultimately deliver new therapeutic 
strategies. This review summarises the current status on the role of the microbiota in autoimmune 
diseases.
INTRODUCTION
The concept of the human metaorganism arose with the realisation that we harbour many 
trillions of microbes on and within the human body.1 These microbes are located at the host-
environmental interface, such as the skin, the GI tract, the genital tract and respiratory 
mucosal barrier. All genes of our microbial cohabitants constitute the micro-biome, and this 
microbiome outweighs the genetic contribution of the host by 10-fold.1 Our personal 
microbial world is rich in diversity and many thousands of species survive and thrive within 
us. The sheer enormity of this microbial community has become apparent over the last 
decade as technology, such as sophisticated sequencing techniques and high throughput 
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technology, has allowed for the identification of the microbial community and analysis of its 
function. It is clear that our micro-biota is not a mere bystander; they have coevolved with us 
and are pivotal to normal development and homoeostasis, from a metabolic, trophic and 
protective capacity.23
The intestinal microbiota interacts with the adjacent mucosal environment directly, impacts 
intestinal permeability, and influences local and systemic inflammatory activity.4 There is 
also an indirect crosstalk between the microbial community and the host via their 
metabolites; for example, digestion of plant polysaccharides by gut bacteria yields short 
chain fatty acids and these in turn modulate host mucosal immune response by various 
mechanisms, including promotion of regulatory T cells.5 The composition of our microbiota 
is not static, but changes with age, geography and is influenced by many external factors, 
such as diet and medication.6–8
Large global consortia such as the US Human Microbiome Project seek to provide 
knowledge on microbial composition in health and disease and it is clear that an appreciable 
interindividual and intraindividual variation exists, influenced by many external factors.9 It 
is now known that alteration in the balance of intestinal microbial species leading to a 
dysbiosis is associated with many disease susceptibilities. Examples of this include obesity,4 
multiple sclerosis (MS),10 malignancy,11–13 liver disease,1415 and GI pathology such as IBD,
16 but the precise mechanism of this microbial influence in disease pathogenesis remains 
elusive and is now becoming a major research focus.
Within this exploration of the relationship between the gut microbiota and disease, there has 
been interest in the role of the microbiota in the pathogenesis of systemic and organ targeted 
auto-immune disease. Autoimmune diseases are characterised by serological evidence of 
autoantibodies, pronouncing lack of tolerance and self-directed immune response. Several 
autoimmune diseases such as type 1 diabetes (T1D) and rheumatoid arthritis (RA) contribute 
significantly to global morbidity and mortality. Understanding the role of the microbiota in 
these diseases may offer novel insight into factors that initiate and drive disease progression, 
stratify patient risk for complications and ultimately could deliver new therapeutic strategies.
Reflecting the importance of this topic, the role of the microbiota in autoimmunity was the 
subject of a 2014 National Institutes of Health (NIH) symposium, cosponsored by the 
Society for Women’s Health Research. This review aims to summarise current data on the 
role of the microbiota on auto-immunity, and concludes by summarising points raised within 
the closing discussion at the NIH symposium.
TYPE 1 DIABETES
T1D is a chronic, proinflammatory autoimmune disorder characterised by immune-mediated 
destruction of the pancreatic β cells, resulting in insulin deficiency and hyperglycaemia. 
Clinical manifestation of T1D usually presents in childhood and adolescence and incidence 
of this disease continues to increase globally.1718 There is clear evidence of a genetic 
susceptibility to T1D.19–21 However, given the 50% concordance rate in monozygotic 
twins22 and the fact that immigrants exhibit risk associated with place of residence rather 
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than origin23 there clearly is a central role for environmental factors in T1D pathogenesis. 
This has been explored extensively and the main aspects of environmental risk focus on diet, 
including neonatal exposure to bovine derived milk products, age at weaning and early 
exposure to gluten (reviewed in ref.24) as well as a potential infective component such as 
childhood viral infection, particularly Enterovirus given the seasonal timing of clinical 
presentation.25
In light of the emerging evidence that the gut microbiome has a strong and broad impact on 
health and disease, the question of whether the gut microflora could impact T1D has arisen. 
Indeed, a growing evidence base from animal and human studies suggests that changes in 
the gut microbiome may precede the onset of T1D and are associated with progression from 
detectable autoantibody levels in high-risk asymptomatic individuals through to those with 
clinical disease and this has been reviewed elsewhere.26–30
Several animal models of T1D exist.31 Of these, the non-obese diabetic (NOD) mouse and 
the biobreeding diabetes-prone rodent model exhibit similar genetic predisposition and 
pathological disease progression to human T1D and have been used to explore the 
relationship between the gut microbiome and T1D.
Manipulation of the gut microbiota by different approaches, such as treatment with 
antibiotics,32–35 exposure to acidified water,3637 exposure to pathogenic and non-pathogenic 
bacterial strains,3638–40 housing in germ-free conditions,3241 along with temporal analysis of 
faecal microbiota preceding and during disease development has revealed the importance of 
the colonic microbial community in the pathogenesis of T1D. However, many conflicting 
reports exist in the literature and highlight the complexity of this association. It is clear from 
the evidence that the gut microbial community influences host immunity and this could 
ultimately aid emergence of disease. For example, Wen et al32 revealed the importance of 
crosstalk between host and gut microbiota in T1D pathogenesis. MyD88 (myeloid 
differentiation primary response protein 88) is pivotal to bacterial sensing and downstream 
signalling host innate immune response, and genetic silencing of this bacterial sensor in 
specific pathogen-free NOD mice interrupted development of T1D as compared with wild 
type controls. In contrast, the same genetically altered mice, either raised in germ-free 
conditions or treated with antibiotics to disrupt gut commensal bacteria, developed disease. 
This indicates protection was mediated by a constituent of their gut microbial community 
although the underlying mechanisms are not fully understood. Certainly, changes in the 
intestinal microbiota composition were demonstrated in conjunction with loss of the ability 
to sense microbes via MyD88. A follow-on study showed that faecal bacterial transplant 
from the MyD88 null protected mice conferred protection to the wild type diabetes-prone 
strain, and altered mucosal immunity and faecal microbial composition of the recipient.40 
The importance of innate pattern recognition receptors in microbial sensing of the gut 
microbiome in directing the downstream host immune response and development of T1D 
has been validated elsewhere.3442 Alkanani et al34 identified a crucial role of an additional 
innate microbial sensor upstream of MyD88, Toll like receptor (TLR)3, but not TLR9 in this 
capacity to modulate the emergence of T1D.
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The pH of drinking water, particularly low acidity, influences the composition of the gut 
microbiome and incidence of T1D.3637 Exposure of female NOD mice to acidified water 
resulted in a differential induction speed and severity of insulitis and hyperglycaemia, 
associated with intestinal dysbiosis, along with increased gut and systemic proinflammatory 
status.36 Conversely, Wolf et al37 reported an increased incidence of T1D in mice exposed to 
neutral water, with a protective role seen along with exposure to acidified water. The 
differences in study design suggest that the timing of microbial disruption, in this case 
through exposure to acidified water, is a key consideration.37 Alteration of the microbiome 
at a very early age, such as in the newborn period when the gut microbiota is being 
established and thus long before onset of disease, may impact subsequent disease induction 
in genetically susceptible individuals.
Exposure to vancomycin, an antibiotic to specifically target Gram-positive bacteria, in infant 
and adult NOD mice was associated with a decreased incidence of T1D, and lower levels of 
blood glucose and insulitis scores, respectively.33 Notably, a single species, namely 
Akkermansia muciniphila emerged as a dominant potentially protective species in this 
context. This protective effect of antibiotic treatment in diabetes-prone rodents has been long 
recognised.4344
Autoimmune disease tends to be prevalent in female mice preferentially. Could the gut 
microbiota influence this gender-specific preponderance? Markle et al39 reported that 
microbial exposures early in life impacts sex hormone levels and alters progression to T1D 
in the NOD mouse. Indeed, transplant of faeces from adult NOD mice into immature female 
mice led to increase in testosterone and protection from T1D.
How does this data from preclinical models translate to human disease? There have been 
several human studies that have confirmed the association between the gut microbiota and 
risk of T1D.45 The main outcomes from these studies are presented in table 1. Children with 
T1D have a low abundance of butyrate-producing bacteria.4647 Gut bacterial diversity lacks 
stability, confers differential changes over time in islet autoantibody-positive children as 
compared with nonautoimmune matched controls and children with T1D have more 
variation between individuals.48 As such, children with propensity to autoimmune diabetes 
yield an increase in faecal Bacteriodetes and reduction in Firmicutes over time from their 
early childhood years, potentially even before T1D clinically develops, representing a 
composition that is opposite to that seen in control subjects.464849
Interestingly, akin to that found in the preclinical models, Brown et al reported a reduction in 
Akkermansia spp in those with early disease.47 As such, a greater proportion of these mucin-
degrading bacteria species, as well as butyrate secreting bacteria, were observed among 
healthy controls when compared with a small number of T1D cases at time of clinical 
presentation. In comparison, bacteria capable of producing non-butyrate short chain fatty 
acids were higher among T1D cases.47 From a mechanistic perspective, metabolic focused 
gene expression analysis of the microbiome revealed that gut bacteria display different 
metabolic functional capabilities between the two groups.
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However, this association is far from clear as a recent prospective stool collection study on 
young children did not confirm these findings of change in microbial diversity in those who 
developed anti-islet autoimmunity. However, despite this, the interactions between gut 
microbes were distorted in this group.50 In another study, although newly diagnosed children 
were identified as carrying an increase in Bacteroides, this dysbiosis had returned to the 
status of control subjects in those who had received 2 years of glucose normalising 
treatment.51
Overall, most would agree that T1D is associated with a change in gut microbial 
composition. Certainly, it seems that no single species from the gut microbial community 
has emerged as a causative agent. Rather, in genetically susceptible individuals, there is 
emerging evidence that dysbiosis within the gut micro-biota and interruption of microbial 
colonisation in early life, maybe even as early as birth or the neonatal period, is associated 
with emergence and progression of T1D. In line with this, babies born by caesarean section 
have a >20% increased risk of developing T1D.5253 It has been reported that birth mode 
impacts infant intestinal colonisation.54 The speculation is that caesarean delivery is 
associated with a lack of exposure to maternal microbiota and impacts infant intestinal 
colonisation conferring risk of future autoimmunity in genetically susceptible individuals. In 
fact, it may be that environmental influences on the intestinal microbiota can even extend to 
in utero exposure. NOD mice given a broad spectrum antibiotic cocktail during gestation 
bore offspring with a lower gut microbial diversity and a modulation of T cell phenotype in 
the mesenteric lymph nodes (increased CD3+CD8+ T cells) and Peyer’s patches of the 
intestine (reduced CD4+CD25+, but not Foxp3+ Treg subgroup). However, this only 
impacted emergence of hyperglycaemia to a minor level at 20 weeks of age and this risk did 
not persist into later life.35
The next consideration is whether a particular gut microbial community is linked to cause or 
effect in disease pathogenesis. Is the gut microbial dysbiosis an initiator of T1D, a 
perpetrator of increasing progression or a consequence of other pathological features? This 
remains unanswered. The immune mechanisms involved in islet cell destruction have been 
extensively studied and include pathogenic T cells, shift in B cell phenotype, features of 
antigen presentation, and distorted immunoregulatory mechanisms.55 All the human studies 
reporting an association between altered gut microbiota and T1D have not explored this 
aspect of disease pathogenesis, likely a consequence of easy access to faecal sampling, offset 
against the invasive nature of mucosal biopsy that would not normally be pursued as part of 
diagnosis and management per se. From preclinical animal models, it is clear that changes in 
gut micro-biota or GI microbial exposures are associated with differential host immune 
response, including change in splenic or GI mucosa T cell phenotype,36–384056 for example, 
modulation of T helper cell (Th)17 response. Whether this Th17 association is pathogenic or 
protective, remains under debate.57 Additionally, it has been shown that breakdown of the GI 
epithelial barrier integrity is present in T1D, with increased gut permeability.58–61
It is inherently difficult to assess causality in human studies for several reasons; T1D is an 
early onset disease, with clinical presentation after destruction of islets has occurred. The 
preclinical phase of early islet autoimmunity is asymptomatic, and there is no biomarker that 
will predict disease in the general population. The aetiology is multifactorial and it is 
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difficult to fully account for confounding factors. In addition, all human studies to date have 
used faecal samples for analysis and the question of whether this, as opposed to mucosal 
biopsy derived analysis, reflects the true status of the microbiome in T1D remains 
unanswered.
Several large global collection consortia are ongoing that will yield powerful data from 
prospectively collected data. There are several of these, for example, The Environmental 
Determinants of Diabetes in the Young study, and Diabetes Prediction and prevention 
Project study. The ultimate question is whether the colonic microbiota can be manipulated to 
therapeutic advantage for T1D. More likely, this strategy may be of greater benefit to 
prevent the onset of T1D in high-risk individuals, such as those receiving antibiotics or other 
treatments in the neonatal period that may alter gut microbial acquisition and increase risk of 
T1D in later life.
COELIAC DISEASE
Coeliac disease, like other autoimmune conditions, requires genetic susceptibility and 
environmental influences.6263 This autoimmune disease is unique in that the main 
environmental factor is known, well characterised and therapeutically targeted. This 
environmental trigger in question is dietary gluten, derived from wheat and other related 
grains. Gluten, composed of gliadin peptides and glutenin, evokes a predominantly T cell 
mediated mucosal response in the proximal small bowel,64 with the cytokine interleukin (IL) 
15 playing a pivotal role in the immunopathogenesis.65 This results in the characteristic 
pathological characteristics of progressive villous atrophy, distorted crypt architecture and 
increase in intraepithelial cells, leading to a reduction in absorptive capacity and emergence 
of GI and extraintestinal symptoms.626366 However, there is often a lag of many years after 
gluten exposure until disease manifests serologically or clinically. Indeed, adult onset 
coeliac is not uncommon, and therefore this suggests that additional environmental 
influences are required in coeliac disease pathogenesis.
Concordance rates amongst monozygotic twins are high at more than 80%, compared with 
10% in dizygotic twins,6768 highlighting the importance of genetic susceptibility in this 
disease pathogenesis. HLA class II haplotype DQ2 or DQ8 are the most characterised 
genetic determinant.6263 Carriage of these haplotypes plays a pivotal role in the presentation 
of the gliadin peptides to CD4+ T cells. This is not the whole story, with genome wide 
association studies and high throughput technology identifying many other susceptibility 
genes.69–71
Coeliac disease is thought to affect 1% of the global population, and has been increasing in 
prevalence at a striking rate; doubling over 20 years in a Finnish population72 and increasing 
fourfold in a US population.73
There are well-characterised autoantibodies available for serological diagnosis and 
screening, namely tissue transglutaminase IgA antibody and anti-endomysial IgA antibody. 
Both of these display high specificity and sensitivity.626366
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As a disease of the GI tract, there has been florid interest over several years as to whether the 
gut microbiota could be implicated in the pathogenesis of coeliac disease.6274 Given the 
proximal location of pathology in coeliac disease, the microbiota of the duodenum has been 
the focus of investigation in this context. Despite the hostile conditions of the proximal small 
bowel with fluctuating pH, digestive enzymes and bile, and robust peristalsis, a distinctive 
collection of bacteria appear to survive in this environment, dominated by Streptococci, 
Bacteroidetes, Proteobacteria and clusters of Clostridium sp.75–78 Initial analysis employed 
conventional culturing or limited molecular techniques and reported differences in duodenal 
mucosal biopsy or faecal stream bacteria associated with coeliac disease.7479–84 There has 
been no unifying pattern to identify a distinct bacterial composition or diversity that marks 
presence of coeliac disease, nor successful treatment. Overall, there appears to be a trend for 
abundance in Firmicutes and Bacteroidetes over several studies, in adults and children, 
respectively. However, there are other reports with opposing observations. The inconsistency 
of the findings in these studies is a reflection of several issues; geographical difference with 
undoubted impact on diet (dictated by culture) and genetic susceptibilities, differences in 
experimental methodology including culture versus culture-independent, the low number of 
patients included in analysis, and the origin of the material to be tested, that is, faecal versus 
mucosal biopsy.
With the advent of increasingly sophisticated technology, most recent analyses have used 
sequencing and other high-throughput molecular analysis and yielded conflicting results 
with no dramatic or distinctive dysbiosis of the duodenal micro-biota at either the phylum or 
genus level in children with coeliac disease compared with healthy controls.76–78
Therefore the debate on whether the microbiota is associated with disease pathogenesis is 
ongoing. If a component of the intestinal microbiota was a driving causative factor for 
initiation and progression of coeliac disease, one may expect an obvious candidate to emerge 
from analysis on adults and children, and to revert to that seen in an individual without 
coeliac disease, with successful treatment. This has not as yet emerged to date, but this is 
still an active field and therefore the debate goes on.
Nevertheless, there have been some published reports of how changes in the intestinal 
microbiome may influence underlying mucosal immune response. Sanchez et al85 used an in 
vitro system to show that exposure of Caco-2 cells to digested gliadin and specific 
Bacteriodes sp resulted in increased proinflammatory cytokine profile and disruption of 
permeability. Exposure of dendritic cells to intestinal bacterial species, such as 
Enterobacteria or Bifidobacteria, led to altered phenotype and function. When these cells 
were subsequently cocultured with Caco-2 epithelial cells, an altered expression of proteins 
involved in intestinal permeability was identified.86 When considering animal models of 
coeliac disease, there is no spontaneous model in small rodents. An induced rat model has 
been widely used (germ-free Wistar rats exposed to gliadin immediately after birth), along 
with transgenic mice exhibiting HLA genetic susceptibilities akin to human disease.87 These 
in vivo models have been employed to understand the underlying immune activity in coeliac 
disease initiation and progression. With regard to the role of the microbiota in this process, 
exposure to specific bacterial strains in vivo does impact epithelial permeability and 
underlying mucosal immunity. For example, administration of the intestinal commensal 
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Bifidobacterium longum to the induced rat model is protective to emergence of disease and 
associated with increased mucosal anti-inflammatory activity such as increased IL-10.8889 
However, this strategy has been directed at exploring the effect of targeted exposure of 
single agents, rather than an assessment of total micro-biome composition dysbiosis in its 
entirety. There are additional models of coeliac disease emerging in the literature;87 for 
example transfer of gliadin presensitised CD4+CD25−CD45RBlow T cells into a Rag-
deficient murine host,90 and these novel models may be able to shed some new light on the 
role of the microbiota in coeliac pathogenesis. To date, the vast majority of studies assessing 
the microbiota in coeliac disease has used human faecal and/or biopsy tissue specimens, as 
discussed below, rather than employ animal models. The main findings from the assessment 
of the microbiota in coeliac disease are presented in table 2.
Olivares et al91 provided evidence that underlying genetic status can influence composition 
of the developing microbiota. Faecal stream pyrosequencing analysis from infants deemed 
high or low genetic risk of coeliac disease (HLA-DQ2 carriers or non-HLA-DQ2/8, 
respectively) was assessed for intestinal microbial composition. Interestingly, HLA status 
was associated with differential faecal bacterial composition, with those deemed high risk 
carrying increased Firmicutes and Proteobacteria, and reduced Actinobacteria, suggesting 
genetic status may impact the composition of the evolving intestinal microbiota. Whether 
this association leads to emergence of disease remains unclear and is under investigation. 
Similarly, Sellitto et al92 performed dynamic stool sequencing analysis from birth to age 2 
years, in infants genetically at high risk of coeliac disease. They reported the temporal 
evolution of the intestinal microbiota in this cohort, and asked whether this changed in 
accordance with timing of dietary gluten exposure. As expected, faecal bacterial 
composition changed over time. However, regardless of timing to gluten exposure, the 
microbiota did not reach that expected of a healthy adult by 24 months. In particular, this 
high-risk group carried much less Bacteroidetes. Close monitoring of these children for a 
longer term may give clues as to whether this dysbiosis in infancy and early childhood 
impacts disease emergence.
Nistal et al76 report a change in bacterial richness between adults and children with coeliac 
disease, and provide evidence of a dysbiosis between treated and untreated adults, especially 
when considering unknown bacterial composites. Similarly, Schippa et al83 assessed the 
duodenal microbiota in children before and after introduction of a gluten-free diet in the 
same individuals and identified around 65% similarity, with increased diversity in the active 
state compared with after treatment. It has been suggested that these observations may 
indicate that the duodenal microbiome can be modulated by exposure to dietary gluten. An 
alternative explanation is that it may be modulated by differences in mucosal inflammatory 
activity with withdrawal of the dietary stimulant.
Coeliac disease can present as a variety of symptoms, including classical GI or 
extraintestinal symptoms, such as the characteristic skin lesion, dermatitis herpetiformis. 
The factors that dictate how an individual will manifest their disease clinically are unknown. 
Could the microbiota be involved in this process? Wacklin et al93 assessed this and found 
that patients presenting with GI symptoms or anaemia clustered separately on principle 
coordinate analysis than those with skin presentation, had a reduced duodenal mucosal 
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bacterial diversity and differential bacterial population characterised by an increase in 
Proteobacteria, and a reduction in Bacteroidetes and Firmicutes.
It has recently been shown that bacteria with enzymatic ability to degrade gluten-derived 
peptides are present in the oral cavity of healthy individuals.94 It is unknown whether there 
is an altered abundance or functional ability of these bacteria in those with coeliac disease. 
Treatment strategy currently rests on adherence to a gluten-free diet, but this can be difficult 
to rigorously achieve, and exclusivity is a challenge. Therefore alternative and adjunct 
therapies are under development. One of these adjunct strategies uses oral recombinant 
glutenase and has reported a successful outcome in a Phase II trial.95 It may be that lessons 
from endogenous oral bacteria can assist this effort. There has been some interest in whether 
the oral microbiome differs in those with coeliac disease. Francavilla et al96 showed that 
children treated for coeliac disease do have an altered oral microbiome, characterised by 
reduction in diversity and a change in abundance of various bacterial species. Specifically, 
there was an increase in Bacteroidetes and a reduction in Actinobacteria with representative 
changes in the oral metabo-lome. The authors suggest that this parameter could in turn be 
developed as a non-invasive screening tool for coeliac disease in the future.
RHEUMATOID ARTHRITIS
RA is a chronic, systemic, polyarthritic disease characterised by synovial inflammation and 
erosion of bone and cartilage, progressing to functional disability.9798 Longitudinal studies 
indicate that autoimmune aspects of RA are initiated years before clinical manifestations of 
the disease are evident,99 with circulating anticyclic citrullinated peptide antibodies and 
rheumatoid factor (RF) evident up to a decade prior to emergence of clinical disease.100 
ACPAs are specific biomarkers for RA, present in 70–80% of patients with RA, and are 
typically associated with worse outcomes.97 RA affects up to 1% of adults worldwide9798 
and is multifactorial in aetiology, requiring interaction between genetic and environmental 
factors for its onset.97–99
As with T1D, genetic factors are important97101 but account for only a proportion of risk 
susceptibility for RA, and genetic predisposition does not guarantee the development of RA.
99 Although twin studies show a higher concordance in monozygotic twins (12–15%) than in 
dizygotic twins (3.5%), the overall concordance is low and indicative of a pivotal role for 
environmental influences.102103
There is ongoing debate on whether RA may be initiated by an infectious microorganism,
98104 and many bacteria have been proposed in this capacity, such as Mycoplasma 
fermentans,105 Escherichia coli106 and Proteus mirabilis.107108 This idea of ‘molecular 
mimicry’ has existed for at least a century, but has never been definitively proven.104 As part 
of this assessment, the oral microbiota has been explored in RA pathogenesis. Belief in the 
so-called ‘oral sepsis hypothesis’ resulted in tooth extraction as a common treatment for RA
—a practice that dates back to the early 1900s,109 which continued for several decades. 
Current literature continues to support associations between RA and the microbiota. The 
main findings from this assessment are presented in table 3. The periodontal microbiota has 
been a particular focus. Animal models indicate that the periodontal pathogens 
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Porphyromonas gingivalis and Porphyromonas nigres-cans significantly aggravate the 
severity of collagen-induced arthritis (CIA), with bacterially induced IL-17 directly 
correlated with intensity of arthritic bone erosion.110 Moreover, in humans, patients with 
new-onset RA have a higher prevalence of severe periodontitis at RA disease onset despite 
their young age and paucity of smoking history and normal oral hygiene routine.111 Patients 
with RA have more tooth loss and greater periodontal friability despite oral hygiene 
comparable to that in healthy controls112 and the severity of periodontal disease is correlated 
with RA disease activity.113 After controlling for a variety of confounding factors, including 
RA status, age, gender, education,114 smoking,111115 alcohol consumption and body mass 
index (BMI), only RA status and age predict periodontal disease.114 In addition, patients 
with RA who receive treatment for periodontal disease show improvements in RA with 
concomitant decreases in APCAs, anti-P. gingivalis antibodies,116 and proinflammatory 
cytokines such as TNF-α.117
The presence of antibodies to P. gingivalis is associated with the presence of RA-related 
autoantibodies in patients with RA,118 as well as individuals at risk for, but who have not yet 
developed, RA.115 Levels of antibodies to P. gingivalis correlate with levels of APCAs and 
RF, which are indicative of RA disease activity.115 The question is whether this association 
between the oral microbiota and RA directly impacts pathogenesis. DNA of P. gingivalis119 
and P. nigrescens120 are found in serum and synovial fluid of patients with RA. Similarly, P. 
gingivalis111 and P. nigrescens119120 are present in subgingival dental plaque and synovial 
fluid of patients with RA. Thus, it has been speculated that a particular species of 
Porphyromonas, perhaps working in concert with oral bacteria from other genera (including 
Anaeroglobus, Prevotella and Leptotrichia) may potentially serve as an environmental 
trigger for RA in genetically susceptible individuals.111 However, it remains to be definitely 
determined whether local periodontal disease precedes the development of RA, or whether 
periodontitis could be an extra-articular feature of RA, in which case periodontal tissue and 
joints are preferential targets of the same auto-immune processes.111 To explore this 
relationship, Marchesan et al121 infected a CIA mouse model with P. gingivalis, and reported 
increased severity of joint disease, associated with systemic proinflammatory cytokine 
profiles representative of activation of the Th17 pathway.
P. gingivalis is the only known prokaryote carrying a gene capable of expressing the 
endogenous peptidylarginine deiminase enzyme, required for the conversion of arginine 
residues to citrulline. Thus, P. gingivalis could be involved in the pathogenesis of 
autoimmunity by facilitating the generation of citrullinated proteins that can foster loss of 
immune tolerance and production of APCAs. It has been hypothesised that individuals who 
possess a genetic predisposition (or other susceptibility factors) together with P. gingivalis 
within their oral microbiota are more likely to develop immune responses to citrullinated 
antigens. As an example, patients with RA can be positive for antibodies to citrullinated α-
enolase peptide-1 (CEP-1) that cross react with bacterial enolase and there is a correlation 
between the presence of APCA and CEP-1, perhaps due to a shared epitope.122
Recently, there has been interest in the role of the respiratory tract microbiota in RA. It is 
suggested that, by virtue of their constant exposure to bacterial antigens, the lungs may be a 
potential site of early events that facilitate the initiation and, or progression of RA. While 
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there have not been any studies that directly examined the role of the lungs and their 
microbiota in patients with RA, several studies suggest that the lungs may be susceptible to 
proinflammatory microbiota originating from periodontal tissue.123 First off, the respiratory 
mucosa houses their own unique set of microbiota that can be come perturbed in disease 
states.124125 In addition, the lungs are a site of local citrullination, which can be accelerated 
by smoking in the absence of RA.126 Moreover, patients with early RA and at-risk, 
seropositive individuals without RA, show signs of inflammatory associated airway injury, 
such as bronchial wall thickening, and air trapping.127
Could the intestinal microbiota play a pivotal role in the pathogenesis of RA?128–130 Animal 
models of RA can be rescued or exacerbated by elimination or exposure to gut-residing 
bacteria, respectively.131132 For example, the K/BxN T cell receptor transgenic mouse 
model of spontaneous inflammatory arthritis is attenuated by germ-free rearing or 
modulation of gut micro-biota with antibiotic treatment. In contrast, segmented filamentous 
bacteria related to Clostridium can induce proinflammatory small bowel lamina propria 
responses in this mouse model of arthritis, via an increase in Th17 cells and subsequent 
exacerbation in arthritic pathology.132 Another spontaneous murine model of inflammatory 
arthritis, namely the IL-1 receptor antagonist-knockout mouse (IL-1RA−/−), also showed no 
development of arthritis in germ-free conditions.131 Crucially, exposure of these germ-free 
mice to Lactobacillus bifidus, a Gram-positive anaerobic commensal of the GI tract, 
exacerbated disease. Elegant use of further TLR genetic knockout in this model revealed that 
TLR signalling is intimately linked to arthritis pathogenesis; IL-1RA−/−TLR2−/− mice 
displayed exacerbated arthritis through reduction in regulatory T cell response. In 
comparison, IL-1RA−/−TLR4−/− mice were protected from arthritis through reduction in 
Th17 T cell response. These results suggest that innate receptor sensing, potentially of gut 
microbiota, may be a crucial step in disease pathogenesis and provides insight into a gut to 
joint mechanism in disease pathogenesis.
Mice carrying arthritis susceptibility genes (HLA DRB*0401) have a different composition 
of gut microbiota compared with genetically resistant counterparts (HLA DRB*0402), rich 
in Clostridium-like bacteria. This was associated with differential Th17 gene transcripts in 
the gut, altered mucosal immune function and increased gut permeability.133 Dorożyńska et 
al134 showed that modulation of the gut flora with antibiotic treatment reduced disease 
severity in the CIA animal model of RA, along with differential cytokine response in 
mesenteric lymph nodes.
How does this translate to human disease? Vaahtovuo et al135 identified a dysbiosis of faecal 
microbiota in patients with newly diagnosed RA compared with fibromyalgic controls, 
characterised by a decrease in Bifidobacteria and Bacteroidetes. Similarly, faecal 16sRNA 
sequencing has shown that patients with new onset RA carry a distinctive enterotype of gut 
micro-biota characterised by an abundance of Prevotella copri and a relative lack of 
Bacteroides.136 P. copri robustly correlates with disease severity in patients with new-onset 
RA although whether this impacts the initiation or progression of autoimmunity is unclear. 
However, this species of bacteria is capable of expanding to dominate the commensal 
microbiota and exacerbates experimental colitis when delivered to mice by gavage.136
McLean et al. Page 11













IS THERE ANY EVIDENCE FOR THE ROLE OF THE MICROBIOME IN OTHER 
AUTOIMMUNE DISEASES?
Autoimmune diseases can occur at any site in the body, and indeed there is a long list of 
diagnoses in this category. Again these occur due to a prescribed genetic susceptibility and 
largely unknown environmental influences, and manifest serologically with evidence of 
autoantibody production. Examples include autoimmune thyroiditis, autoimmune 
pancreatitis, Sjogren’s syndrome, systemic lupus erythematosus (SLE) and autoimmune 
liver diseases such as autoimmune hepatitis and primary biliary cirrhosis. Given the evidence 
for the role of the microbiota in the pathogenesis of T1D, RA and coeliac disease as 
discussed previously, there is an emerging interest in whether the micro-biota may be 
implicated in other, often rarer autoimmune conditions. This is certainly in its infancy, but 
there are a few publications appearing in the literature to this effect.
Zhou et al137 recently analysed the faecal microbiota from patients with hyperthyroidism 
compared with healthy controls. Denaturing gradient gel electrophoresis analysis revealed an 
increased bacterial diversity in those with hyperthyroidism, with a reduction in Lactobacillus 
and Bifidobacteria. To date, this appears to be the only study of this nature in thyroid 
disease. However, a clue that the intestinal microbiota may be an important environmental 
factor appeared over a decade ago in the literature; disease susceptibility of a rat model of 
auto-immune thyroiditis could be affected through modulation of the gut microbiota.138 
Animals raised in specific pathogen-free conditions were less susceptible to disease. In 
contrast, treatment with oral antibiotics and stool transplantation from conventionally reared 
animals into specific pathogen-free rats, resulted in exacerbated disease. Furthermore, this 
effect was seen in off-spring when this modulation was given to mothers during gestation.
Sjogren’s syndrome and SLE are characterised by the emergence of anti-Ro66/Sjögren’s 
syndrome antigen A antibodies, but the initiating event leading to this is unclear. As loss of 
tolerance by T cells is known to be necessary in this process, Szymula et al139 explored 
whether these T cells could be activated through recognition of gut derived bacterial 
antigens. They created Ro60 reactive T cell hybidomas from mice transgenic for the genetic 
susceptibility for Sjogren’s syndrome and SLE, and tested their ability to react to different 
bacteria-derived peptides. They found reactivity to three peptides derived from oral 
commensal bacteria, and also four peptides from gut-derived commensal bacteria; three of 
the latter belonged to Bacteroides spp. This suggests that autoreactive T cells responsible for 
these autoimmune disorders may be primed in the gut by exposure to commensal 
microbiota. However, as yet, there are no reports of intestinal microbiota analysis in SLE 
and Sjogren’s syndrome. Indeed, from animal studies using the NZB mouse model that 
spontaneously develops autoimmune features likened to human SLE, the potential role of the 
microbiota is less clear, in that there is little difference in disease emergence and 
autoantibody formation between germ-free and conventionally raised litters.140 However, 
disease characteristics can be modified by dietary change. The mechanism of this is unclear, 
but it has been hypothesised that this may reflect modulation of the gut commensal bacteria.
140
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Ankylosing spondylitis (AS) is associated with a clear genetic susceptibility of HLA-B27 
positivity and is characterised clinically by spinal and large joint arthropathy, enthesopathy 
and other systemic manifestations. There is a strong association between AS and 
microscopic or overt IBD.141142 Serological evidence of anti-cBir antibodies in patients with 
AS have implicated flagellated bacteria in this disease.143 Animal models of AS with HLA-
B27 genotype do not develop disease in germ-free facilities.144 These findings have fuelled 
interest in whether the gut microbiota could be involved in this disease pathogenesis. A 
small human study in 2002 using denaturing gradient gel electrophoresis techniques 
assessed this question and did not find any clear dysbiosis.145 The same group went on to 
show that circulating T cells from patients with AS evoked a diminished IL-10 cytokine 
response after exposure to autologous faecal Bacteriodes sp.146 Recently, Lin et al147 have 
shown that carriage of the human transgene HLA-B27 in rats itself alters the caecal 
microbiota, although the mechanism by which this then crosstalks to the host immune 
system and impacts phenotype remains unclear. To date, there are no additional reports of 
human studies assessing the gut microbiota in AS compared with controls that employ high 
sensitivity sequencing techniques.
MS is a chronic demyelinating disorder of the central nervous system (CNS), mediated by a 
predominant T cell driven myelin directed autoimmunity. The initiating factor is unknown, 
although genetic and environmental factors play an important role. The concept of the 
microbiota-gut-brain axis has emerged given that the enteric microbial community has the 
ability to crosstalk with our nervous system,148 for example, gut microbes can secrete 
various molecules that can directly impact enteric neuronal signalling, such as serotonin, 
melatonin or acetylcho-line, and enteric neurons express TLRs and so are able to sense and 
react to the microbial community directly.149 There is a growing body of evidence to show 
that the intestinal microbiota may be implicated in the pathogenesis of this disease (reviewed 
in refs.10149150). The quintessential animal model of MS is the experimental allergic 
encephalomyelitis (EAE) mouse; progressive demyelinating neurological disease is 
precipitated by pathogenic autoreactive T cells induced by simultaneous injection of a 
myelin antigen and bacterial adjuvants. In this model, manipulation of the gut microbiota by 
germ-free rearing151 or antibiotics152–154 confers resistance to disease onset and diminishes 
severity. Re-establishing intestinal colonisation in germ-free resistant mice, for example 
monocolonisation with segmented filamentous bacteria reinstates the disease susceptibility.
151 This protection is mediated by an altered adaptive immune response, characterised by an 
increase in regulatory T cell151153 and IL-10 producing regulatory B cell populations,154 and 
reduction in proinflammatory Th1 and Th17 cells.151152 Similarly, a spontaneous murine 
model of CNS demyelination (SJL/J mice expressing T cell receptor towards myelin peptide 
antigen) is also protected by germ-free rearing, with emergence of disease with gut 
microbial recolonisation,155 and disease pathogenesis implicating autoreactive pathogenic T 
cells and autoantibody producing B cells. Restitution of germ-free EAE mice with intact 
Bacteroides fragilis conferred protection, dependant on capsular polysaccharide A, whose 
presence attenuated disease from a therapeutic and preventative strategy, through promotion 
of IL-10 producing regulatory T cells via TLR2 signalling.156–159 As yet, there is no 
reported assessment of the gut microbiota in human patients with MS and this data is eagerly 
awaited and may yield novel therapeutic targets.
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It is clear that the human microbiota holds a pivotal position in health and disease. The 
enormity of this relationship is just beginning to become apparent as technology allows 
more in-depth analysis of the microbial community we harbour, in composition and 
functionality. In autoimmune disease, there is a clear strong genetic predisposition. The role 
of environmental influences is appreciated but not fully understood for many of these 
diseases and the initiating factor often remains elusive. Autoimmune disease is a complex 
interplay between genetics, environmental exposures and immune function, and there are 
several ongoing unanswered questions; what dictates the spectrum of disease severity? What 
dictates why some individuals with appropriate genotype remain disease-free lifelong, while 
others harbour latent disease or overt clinical pathology? Why do autoimmune diseases 
present in patients of differing ages despite the same environmental exposures? Could the 
micro-biota be responsible for this disparity?
There is clear and increasing evidence that changes in the microbiota are associated with 
some autoimmune diseases as discussed in this review. This dysbiosis in the microbiota is 
associated with several autoimmune diseases, involving the GI mucosa that lies in close 
contact with luminal contents as exemplified by coeliac disease, and also autoimmunity 
targeted towards distant sites, such as the pancreas in T1D and joints in RA. However, for 
now and for the most part, the relationship between the microbiota and autoimmune diseases 
remains an association. The question of ‘cause or effect?’ retains prominent status. Is 
dysbiosis of the microbiota an initiator of autoimmune disease, a perpetrator of increasing 
progression or a consequence of other pathological features? This remains unanswered. It 
appears that the large, global, longitudinal, prospective consortium efforts that are now in 
place, aim to address this point and this is certainly a Herculean task. A strength of these 
efforts is the detail of the design and use of cutting edge technology to maximise and 
thoroughly analyse the data generated. This approach has the power to revolutionise our 
understanding of these diseases and ultimately offer insight into novel preventative or 
therapeutic strategies.
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Table 1
The main outcomes from studies assessing the human gut microbiome in T1D (faecal stream analysis)
Association with T1D compared with control Reference
↓ Butyrate producing bacteria 46, 47
↓ Mucin degrading bacteria (Akkermansia sp) 47
Bacterial metabolic functional capabilities differ 47
Bacterial diversity lacks stability 48
↑ Bacteroidetes, ↓ Firmicutes preceding disease onset 46, 48, 49, 51
Interactions between bacteria distorted 50
Change in microbiome may revert with glucose normalizing treatment 51
No single causative agent identified
TID, type 1 diabetes.
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Table 2
The main outcomes from studies assessing the microbiome in coeliac disease (upper small bowl mucosal 
biopsies and faecal stream analysis)
Association with coeliac disease compared with control Reference
Dysbiosis and ↑ diversity in adults and children 76, 81–84
No unifying pattern or distinct composition or diversity
↑ Firmicutes in adults 76, 83
↑ Bacteroidetes in children 80, 81, 83, 84
↑ Bifidobacterium in children 82, 86
No difference in diversity by microarray HITChip/16S sequencing 77, 78
High genetic risk—↑ Firmicutes 91
High genetic risk—↓ Bacteroidetes 92
High genetic risk—altered diversity 91, 92
No single causative agent identified
Altered oral microbiome 96













McLean et al. Page 25
Table 3
The main outcomes from studies assessing the microbiome in RA
Microbiome site Association with RA compared with control Reference
Oral Porphyromonas Gingivalis and Porphyromonas nigrescans aggravate animal models of arthritis 110, 121
↑ Prevalence of periodontitis in patients with RA 111–115
Evidence of periodontal pathogens in synovial fluid of patients with RA 111, 119, 120
Intestinal Animal models of arthritis exacerbated or rescued by changes in gut microbiome 131, 132, 134
Humans—↓ Bacteroidetes and Bifidobacterium 135, 136
RA, Rheumatoid arthritis.
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